Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Literature DB >> 533575

Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

M Danhof, D D Breimer.

Abstract

Entities: Species

Mesh：

Substances：
Antipyrine

Year: 1979 PMID： 533575 PMCID： PMC1429894 DOI： 10.1111/j.1365-2125.1979.tb01040.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

20 in total

1. The fate of antipyrine in man.

Authors: B B BRODIE; J AXELROD
Journal: J Pharmacol Exp Ther Date: 1950-01 Impact factor: 4.030

2. Metabolic disposition of antipyrine in patients with lung cancer.

Authors: C Tschanz; C E Hignite; D H Huffman; D L Azarnoff
Journal: Cancer Res Date: 1977-11 Impact factor: 12.701

3. Assessment of antipyrine kinetics by measurement in saliva.

Authors: H S Fraser; J C Mucklow; S Murray; D S Davies
Journal: Br J Clin Pharmacol Date: 1976-04 Impact factor: 4.335

4. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.

Authors: C J van Boxtel; J T Wilson; S Lindgren; F Sjöqvist
Journal: Eur J Clin Pharmacol Date: 1976-02-06 Impact factor: 2.953

5. Use of saliva in therapeutic drug monitoring.

Authors: M G Horning; L Brown; J Nowlin; K Lertratanangkoon; P Kellaway; T E Zion
Journal: Clin Chem Date: 1977-02 Impact factor: 8.327

Review 6. Genetic and environmental factors affecting drug disposition in man.

Authors: E S Vesell
Journal: Clin Pharmacol Ther Date: 1977-11 Impact factor: 6.875

Review 7. Factors influencing antipyrine elimination.

Authors: I H Stevenson
Journal: Br J Clin Pharmacol Date: 1977-06 Impact factor: 4.335

8. [On the metabolism of antipyrine (phenazone) in man (author's transl)].

Authors: E Zietz; M Eichelbaum; H J Dengler; G Spiteller
Journal: Arzneimittelforschung Date: 1978

9. Polymorphic hydroxylation of Debrisoquine in man.

Authors: A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal: Lancet Date: 1977-09-17 Impact factor: 79.321

10. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

Authors: M Danhof; E de Groot-van der Vis; D D Breimer
Journal: Pharmacology Date: 1979 Impact factor: 2.547

27 in total

Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

1. The fate of antipyrine in man.

2. Metabolic disposition of antipyrine in patients with lung cancer.

3. Assessment of antipyrine kinetics by measurement in saliva.

4. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.

5. Use of saliva in therapeutic drug monitoring.

Review 6. Genetic and environmental factors affecting drug disposition in man.

Review 7. Factors influencing antipyrine elimination.

8. [On the metabolism of antipyrine (phenazone) in man (author's transl)].

9. Polymorphic hydroxylation of Debrisoquine in man.

10. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

1. Disposition of antipyrine in patients with extensive metastatic liver disease.

2. Biliary excretion of antipyrine and its metabolites after cholecystectomy.

3. Plasma antipyrine half-life can be determined from urine data.

4. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.

5. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.

Review 6. Clinical implications of enzyme induction and enzyme inhibition.

7. The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

8. Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.

9. The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits.

10. Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery.